Heart-Thickening drug trial aims to reverse damage
NCT ID NCT07655362
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether adding baxdrostat (Baxfendy) to standard care can improve heart structure and function in 286 adults with high blood pressure and thickened heart walls. Participants take either baxdrostat or a placebo daily for 12 months, with heart scans and regular checkups to measure changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baxdrostat (Baxfendy)
What this could lead to
If successful, baxdrostat could become a new add-on treatment to help reverse heart thickening and improve heart function in people with high blood pressure.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not improve heart structure more than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Diagnostic Assessment Centre
Toronto, Ontario, M1S4N6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B3H7, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••